NDAORALGRANULEPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
COLESTID (colestipol hydrochloride) by Pfizer is clinical pharmacology cholesterol is the major, and probably the sole precursor of bile acids. Approved for hypertension. First approved in 1977.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLESTID (colestipol hydrochloride) is an oral anion exchange resin bile acid sequestrant approved in 1977 for cholesterol management. It works by binding bile acids in the intestine and preventing their reabsorption, leading to increased cholesterol oxidation and reduced LDL and total serum cholesterol levels. The drug is indicated for hypertension management as part of lipid-lowering therapy.
$0.199MPart D
LOE ApproachingDeclining
Declining Part D utilization (835 claims in 2023) signals small brand team focused on mature market maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating…
Worked on COLESTID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.